Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. ZLAB
Z

Zai Lab Limited (ZLAB)

NGM – Real Time Price. Currency in USD

18.00

+0.49 (2.80%)

At close: Mar 27, 2026, 4:00 PM EDT

18.08

+0.08 (0.44%)

After-hours: Mar 27, 2026, 5:58 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Stock details

Previous close
18$
Day's range
17.85 - 18.46$
52-week range
15.96 - 44.34$
Volume
691 912
Average volume
864 437
Beta
1.11
EPS (TTM)
-1.61
PE ratio (TTM)
N/A
Market cap
2 042 059 877
Shares outstanding
113 447 771
Dividend yield
N/A
Next earnings date
2026-05-12
Sector
Healthcare
Industry
Biotechnology

About the company

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis ... read more
CEO
Ying Du
Country
China
IPO Date
2017-09-20
Employees
1784
Fiscal Year End
January - December
Website
https://www.zailaboratory.com

Revenue Breakdown

Innovative Therapies / 100.00%

News

No Data

There are no news for this stock.

Chart: ZLAB

Loading Chart...

Overall Score

3.6 / 1036%
Financial Strength
7.2
Profitability
2.8
Effectiveness
1
Growth
7.1
Forecast
5.4
Valuation
3.4

Financial Strength

NAMERATIOINDUSTRY5Y TRENDSCORE
Current ratio2.456.0510
Quick ratio2.275.6310
Debt to Equity0.310.307.0
Debt to Assets0.191.048.0
Interest coverage-51.00-16.911.0
Weighted average score7.2

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)
Values in USD (B=Billions, M=Millions, K=Thousands)
METRIC2022202320242025TTM
Total Revenue215M266M399M461M461M
Gross Profit141M171M251M270M270M
Operating Income-404M-376M-282M-230M-230M
Net Income-443M-334M-257M-176M-176M
EBITDA-387M-359M-262M-206M-206M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAMERATIOINDUSTRY5Y TRENDSCORE
Gross margin %51.15-11.73
10
Operating margin %-54.39-24.60
1.0
Net margin %-39.51-172.20
1.0
EBITDA margin %-50.08-201.27
1.0
Cash flow margin %-13.85-156.39
1.0
Weighted average score2.8

Net Margin

Effectiveness

NAMERATIOINDUSTRY5Y TRENDSCORE
ROA-19.33-57.97
1.0
ROE-28.03-63.56
1.0
ROIC-27.66-42.57
1.0
ROCE-7.14-71.10
1.0
Weighted average score1.0

Estimated EPS vs Actual EPS

Forecast

NAMEREVENUE GROWTHEPS GROWTHSCORE
Current quarter10.78-3.644.0
Next quarter11.65-26.964.0
Current year9.06-7.323.5
Next year28.7733.4110
Weighted average score5.4

Analyst Rating

Growth

NAMEREVENUENET INCOMEEPSFCFSCORE
Q/Q10.24-40.58-39.3857.514.8
Y/Y17.9237.842.568.439.8
3y average29.8226.3829.5322.610
5y average66.55-9.091.69-10.383.8
Weighted average score7.1

Revenue Growth Rate vs. Industry

Valuation

NAMERATIOINDUSTRY5Q TRENDSCORE
P/EN/A-5.25
1.0
PEG (5yr expected)N/A0.27
1.0
P/S4.3064.66
6.4
P/B2.802.96
5.0
Weighted average score3.4

DCF Model

DCF Model PeriodN/A
Discount rateN/A
Perpetual growth rateN/A
Revenue 5 year CAGRN/A
FCF 5 year CAGRN/A
Fair value$
Stock price18$

Dividend

NAMECURRENTINDUSTRYSCORE
Dividend yield0.00N/A1.0
Payout ratio0.00N/A1.0
5-year dividend growth rateN/AN/A1.0
Years of dividend increaseN/AN/A1.0
Weighted average score1.0

Fair Value

Fair Value

$1

UndervaluedStock priceOvervalued

$18

Economic Moat

NAMESCALESCORE
Market shareNone1.0
Intangible assetsNone1.0
Switching costsNone1.0
Network effectNone1.0
Economies of scaleNone1.0
Weighted average score1.0
Dividend
1
Economic Moat
1

Octagon View

Strength & Weakness

Company's cash reserves $779.6M significantly exceed its total debt $224.3M, ensuring strong financial flexibility

Total current assets $1.0B exceed Total current liabilities $416.2M, highlighting excellent liquidity

Debt-to-equity ratio (0.3) is well below the industry average (0.3), showcasing prudent financial management

Interest coverage ratio (-51.0x) is dangerously low, suggesting debt repayment risks

Negative free cash flow -$18.4M limits the company's ability to reinvest or pay down debt